Last reviewed · How we verify
Elimite (PERMETHRIN)
At a glance
| Generic name | PERMETHRIN |
|---|---|
| Sponsor | Aurobindo Pharma Usa |
| Drug class | Pyrethroid [EPC] |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
| First approval | 1986 |
Approved indications
- Infestation by Phthirus pubis
- Infestation by Sarcoptes scabiei var hominis
- Pediculosis Prevention
- Pediculosis capitis
- Pediculosis corporis
Common side effects
- Burning and stinging
- Pruritus
- Erythema
- Numbness
- Tingling
- Rash
- Headache
- Fever
- Dizziness
- Abdominal pain
- Diarrhea
- Nausea and/or vomiting
Serious adverse events
- Seizure
Key clinical trials
- Comparison of Permethrin-Based Treatment Strategies Against Scabies in Infants and Young Children (EARLY_PHASE1)
- Ivermectin Safety in Small Children (PHASE2)
- Bortezomib and Pembrolizumab With or Without Pelareorep for the Treatment of Relapsed or Refractory Multiple Myeloma, AMBUSH Trial (PHASE1,PHASE2)
- A Phase 3 Trial Assessing Safety and Efficacy of B-Pa-L in Participants With DR-TB (PHASE3)
- Better Options for Lymphatic Filariasis Treatment (PHASE3)
- Permethrin-treated Baby-wraps for the Prevention of Malaria in Children (NA)
- Repellents as Added Control Measure to Long Lasting Insecticidal Nets (NA)
- Comparison of Permethrin and Ivermectin in Children Greater Than 6 Yrs Age for Treatment of Scabies (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |